Corriere Massacarrarese - Feed

MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026

IMMEDIAPRESS — Wed, 06 May 2026 02:28:56 +0200

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE

GUANGZHOU, China, May 6, 2026 /PRNewswire/ — MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results from its Phase II clinical trial of QA102 in patients with intermediate dry age-related macular degeneration (AMD). Results of the study were presented in an oral presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 annual meeting in Denver, Colorado.

Intermediate dry AMD is a chronic, progressive retinal disease marked by large drusen and pigmentary changes, representing a significant risk for conversion to advanced AMD. As part of the most common cause of irreversible blindness in older adults, its prevalence is rising, affecting nearly 7% of individuals of 65+ years old in the US.

Study QA102-CS201 is a phase 2, double-masked, randomized, placebo-controlled study was conducted in 150 subjects with intermediate atrophic AMD randomized 1:1:1 to oral QA102 200 or 400 mg, or placebo BID for up to 15 months. Following 12-month treatment, the mean change in drusen volume was reduced by 59.2% in QA102 400 mg group relative to the placebo group. Although the primary efficacy endpoint did not demonstrate a statistically significant difference between groups, the growth rate in drusen volume was reduced 118.2% (p=0.017) and the growth rate in square-root transformed GA area reduced by 42.7% in 400 mg group relative to placebo (p=0.026). In general, QA102 demonstrates the potential to slow down the progression of intermediate dry AMD with an acceptable safety profile. (clinicaltrials.gov NCT05536752)

“Intermediate AMD represents the most prevalent stage of the disease, yet remains an area of significant unmet medical need with a lack of therapies to slow or prevent progression,” said Scott Whitcup, MD, an expert in ophthalmic drug development. “The phase II data for QA102 are very encouraging for millions of people affected by intermediate or advanced forms of dry age related macular degeneration,” said Sunil Patel, MD, PhD, a principal investigator of the study.

“We are delighted to present the compelling Phase II data to the global ophthalmology community at ARVO,” said Fred Ouyang, PhD, Chief Technology Officer of MingMed Biotechnology. “QA102 represents a first-in-class oral therapy for atrophic AMD and is the first drug candidate to demonstrate efficacy signals in intermediate dry AMD. We look forward to advancing QA102 into the next phase of clinical development.”

About MingMed Biotech and SmilebiotekSmilebiotek Zhuhai Limited is a subsidiary of MingMed Biotech, dedicated to the development of first-in-class ophthalmology products. The company’s atrophic AMD pipeline includes two novel candidates: QA102, a new chemical entity (NCE), and QA108, a traditional Chinese medicine (TCM).

View original content:https://www.prnewswire.co.uk/news-releases/mingmed-biotechnology-presents-positive-phase-ii-data-of-oral-qa102-for-the-treatment-of-intermediate-age-related-macular-degeneration-amd-at-association-for-research-in-vision-and-ophthalmology-arvo-2026-302763418.html

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. L’Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

—

immediapress/pr-newswire

VERNAL CAPITAL ACQUISITION CORP. ANNUNCIA IL PREZZO DELL’OFFERTA PUBBLICA INIZIALE DA 100 MILIONI DI DOLLARI

IMMEDIAPRESS — Wed, 06 May 2026 01:30:39 +0200

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE

NEW YORK, 6 maggio 2026 /PRNewswire/ — Vernal Capital Acquisition Corp. (NYSE: VECA) (“Vernal”) ha annunciato il prezzo della propria offerta pubblica iniziale (“IPO”) di 10.000.000 di quote al prezzo di 10,00 dollari per quota. Si prevede che le quote saranno negoziate alla Borsa di New York (“NYSE”) con il simbolo “VECAU” a partire dal 6 maggio 2026. Ciascuna quota è composta da un’azione ordinaria e da un diritto a ricevere un quarto di azione ordinaria al completamento di un’aggregazione aziendale iniziale. Una volta avviata la negoziazione separata, si prevede che le azioni ordinarie e i diritti saranno quotati alla Borsa di New York (NYSE) rispettivamente con i codici “VECA” e “VECAR”.

D. Boral Capital LLC agisce in qualità di book-running manager unico dell’offerta. I sottoscrittori hanno un’opzione di 45 giorni per acquistare fino a 1.500.000 quote aggiuntive al fine di coprire eventuali assegnazioni in eccesso. L’offerta dovrebbe concludersi il 7 maggio 2026, fatte salve le consuete condizioni del closing.

Il 5 maggio 2026 la SEC ha dichiarato l’efficacia della dichiarazione di registrazione relativa a tali titoli. L’offerta viene effettuata esclusivamente tramite un prospetto informativo. È possibile richiedere copie del prospetto informativo a D. Boral Capital LLC, 590 Madison Ave., 39th Floor, New York, New York 10022, per telefono al numero (212) 970-5150 o per e-mail all’indirizzo dbccapitalmarkets@dboralcapital.com.

Il presente comunicato stampa non costituisce un’offerta di vendita o di acquisto, né avrà luogo alcuna vendita qualora tale offerta, sollecitazione o vendita risulti illegale prima della registrazione o dell’autorizzazione ai sensi delle leggi vigenti in materia di titoli.

Informazioni su Vernal

Vernal è una società veicolo costituita allo scopo di realizzare una fusione, uno scambio di azioni, un’acquisizione di attività, un acquisto di azioni, una riorganizzazione o un’operazione di aggregazione aziendale analoga con una o più imprese. La ricerca della società target da parte di Vernal non si limiterà a un settore specifico o a una determinata area geografica.

Dichiarazioni previsionali

Il presente comunicato stampa contiene dichiarazioni che costituiscono “dichiarazioni previsionali”, incluse le dichiarazioni sull’IPO di Vernal. Tali dichiarazioni sono soggette a rischi e incertezze che potrebbero causare risultati effettivi sostanzialmente diversi da quelli previsti. Non è possibile garantire il completamento dell’offerta secondo i termini descritti, né che sia effettivamente realizzata. Le dichiarazioni previsionali sono soggette a numerose condizioni, molte delle quali esulano dal controllo di Vernal, comprese quelle indicate nella sezione “Fattori di rischio” della dichiarazione di registrazione depositata presso la SEC. Le copie sono disponibili sul sito web della SEC all’indirizzo www.sec.gov. Vernal declina ogni obbligo di pubblicare aggiornamenti o revisioni delle dichiarazioni previsionali che riflettano eventuali cambiamenti nelle proprie aspettative, salvo nei casi previsti dalla legge.

Contatto

Binghan Yi, CFObinghan@vernal.com
www.vernalspac.com

Logo – https://mma.prnewswire.com/media/2971353/Vernal_Logo.jpg

View original content:https://www.prnewswire.com/it/comunicati-stampa/vernal-capital-acquisition-corp-annuncia-il-prezzo-dellofferta-pubblica-iniziale-da-100-milioni-di-dollari-302763393.html

—

immediapress/pr-newswire

Ultima Markets celebra il decimo anniversario

IMMEDIAPRESS — Wed, 06 May 2026 01:00:29 +0200

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE

10 anni di fiducia. Incentrata sul domani.

EBENE CYBERCITY, Mauritius, 6 maggio 2026 /PRNewswire/ — Ultima Markets Ltd (“UM”), autorizzata e regolamentata dalla Financial Services Commission di Mauritius, celebra il 10° anniversario con il tema “10 anni di fiducia. Incentrata sul domani”. Dal 2016, UM è diventata una delle principali società di intermediazione a livello globale.

Traguardi

UM ha creato uno spazio di trading di livello mondiale grazie a tecnologie ultraveloci e a una rigorosa conformità alle normative, lanciando UM Terminal, MT5 basato sull’IA e l’app mobile. Tra i traguardi più importanti vi sono l’autorizzazione FSC Mauritius (2023), una partnership con Willis Towers Watson, che garantisce la protezione di un fondo di 1 milione di dollari, l’adesione al Global Compact delle Nazioni Unite (2024) e il conseguimento di oltre 50 riconoscimenti entro il 2026.

Celebrare partnership di lunga durata

Tra le iniziative esclusive vi sono:

Le cinque “U”

Valori fondamentali che guideranno il prossimo decennio di UM:

Incentrata sul domani

Guidata dai principi delle Cinque “U”, UM resta incentrata sul futuro, investendo in innovazione, trasparenza ed espansione a livello globale. Sulla base di recenti innovazioni come Copy Trading Pro e UM Academy, l’impegno è fornire il massimo vantaggio nel trading e un’assistenza di eccellenza in tutto il mondo.

Informazioni su Ultima Markets

Ultima Markets Ltd è autorizzata e regolamentata dalla Financial Services Commission di Mauritius, offrendo un’esperienza di trading CFD sicura e regolamentata. In qualità di partner regionale ufficiale dell’FC Internazionale Milano, UM combina la passione per il calcio alla competenza nel trading. Presente in oltre 170 Paesi con più di 1.000 strumenti finanziari, il broker ha ottenuto oltre 50 riconoscimenti, ed è un orgoglioso sostenitore del Global Compact delle Nazioni Unite, in linea con gli Obiettivi di Sviluppo Sostenibile per una crescita responsabile. I prodotti, i servizi e le iniziative riportati in questo comunicato stampa sono offerti esclusivamente da Ultima Markets Ltd. La presente comunicazione non è rivolta ai residenti del Regno Unito, né i prodotti e i servizi qui riportati sono disponibili per i residenti di quel Paese.

Ultima Markets (UK) Limited (“UM UK”) è un’entità giuridica distinta, autorizzata e regolamentata dalla Financial Conduct Authority (“FCA”) nel Regno Unito. UM UK ha ottenuto l’autorizzazione della FCA nel 2025. UM UK non è oggetto del presente comunicato stampa.

Foto – https://mma.prnewswire.com/media/2970209/10th_Anniverary_Company_News_Banner.jpgLogo – https://mma.prnewswire.com/media/2833372/5947525/NEW_vs_OLD_On_white_01_Logo.jpg

View original content:https://www.prnewswire.com/it/comunicati-stampa/ultima-markets-celebra-il-decimo-anniversario-302763369.html

—

immediapress/pr-newswire

ESOC 2026: Rising stroke rates highlight widening ethnic and socioeconomic inequalities across populations, major study finds

IMMEDIAPRESS — Wed, 06 May 2026 00:02:17 +0200

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE

MAASTRICHT, Netherlands, May 6, 2026 /PRNewswire/ — A new study presented today at the European Stroke Organisation Conference (ESOC) 2026 shows that after decades of decline, stroke incidence is rising again, driven by higher rates in some ethnic minority populations and concentrated among socioeconomically disadvantaged groups.

These findings reflect broader patterns seen in diverse urban populations internationally, pointing to widening health inequalities and highlighting an urgent need to improve uptake of cardiovascular risk programmes across all socioeconomic and ethnic groups.

This 30-year analysis examined how the risk of having stroke varied in different ethnic and socioeconomic groups in a population of 333,000 people in South London, of whom 7,726 had a stroke. After a 34% decrease between 1995–1999 and 2010–2014 (from 198 to 131 cases per 100,000 people), the risk of stroke increased by 13% in 2020–2024.

Although overall trends initially improved, the recent rise was not evenly distributed. In 2020–2024, stroke incidence was more than twice as high in Black African (Incidence Rate Ratio [IRR] 2.31; 95% CI 2.03–2.62) and Black Caribbean (IRR 2.00; 95% CI 1.73–2.31) populations compared with the White population.

Rates remained consistently higher in these groups across the study period, with the highest incidence observed among those experiencing socioeconomic deprivation.

Compared with White participants, Black African and Black Caribbean populations were more likely to have high blood pressure (47% and 29% higher prevalence, respectively) and diabetes (92% and 123% higher, respectively), both of which increase stroke risk. Notably, 12% of Black African patients had no diagnosed risk factors prior to stroke, compared with 6.3% of White patients, suggesting gaps in early detection.

Ethnic inequalities were greatest for intracerebral haemorrhage, a severe and often fatal subtype of stroke, with disparities between Black African, Black Caribbean and White populations being more pronounced than for other stroke subtypes.

Lead researcher, Dr Camila Pantoja-Ruiz from King’s College London, stated that these inequalities persisted even after adjusting for clinical severity, socioeconomic status and other clinical factors. Additional analyses found that Black stroke survivors, particularly Black African survivors, were less likely to receive timely follow-up care, with Black African survivors having 34% lower odds of follow-up.

Additionally, Black African populations were found to experience stroke around 10–12 years earlier than White populations on average. These findings highlight the need for earlier prevention and targeted interventions.

View original content:https://www.prnewswire.co.uk/news-releases/esoc-2026-rising-stroke-rates-highlight-widening-ethnic-and-socioeconomic-inequalities-across-populations-major-study-finds-302759136.html

—

immediapress/pr-newswire

Due casi di virus Chikungunya in Toscana a Livorno e Massa: scattano le disinfestazioni

REDAZIONE — Tue, 05 May 2026 23:08:58 +0200

LIVORNO – Scatta l’allerta sanitaria in Toscana dopo la segnalazione di due sospetti casi di virus Chikungunya, la malattia tropicale trasmessa dalla zanzara tigre. Le autorità sanitarie e i Comuni di Livorno e Massa hanno attivato immediatamente i protocolli di emergenza per contenere il rischio di diffusione del virus, che si manifesta con febbri alte, forti dolori muscolari ed eruzioni cutanee.

A Livorno, il dipartimento di prevenzione dell’Azienda Usl Toscana Nord Ovest ha segnalato il ricovero nel reparto malattie infettive di una donna di circa 40 anni. La paziente si era presentata in ospedale con una sintomatologia febbrile e un esantema cutaneo tipico della patologia, contratta con ogni probabilità durante un viaggio in aree tropicali. Sebbene la donna sia ancora ricoverata, le sue condizioni di salute sono definite buone e i medici hanno confermato che non è più in grado di trasmettere la malattia. Per precauzione, il Comune ha disposto una disinfestazione urgente nel raggio di 200 metri dall’ospedale, in via Leonardo da Vinci e in una vasta area compresa tra via Carlo Meyer, via Montebello e piazza Mascagni. L’intervento, inizialmente previsto per le prossime ore, potrebbe slittare a giovedì (7 maggio) in caso di maltempo.

Contemporaneamente, a Massa, il sindaco ha emesso l’ordinanza in seguito a un secondo caso individuato in località Quercioli. Anche qui la misura è scattata per una persona rientrata da un viaggio all’estero. Le operazioni di disinfestazione, programmate dalle 21 alle 24 tra il 6 e l’8 maggio, prevedono trattamenti ‘porta a porta’ con insetticidi adulticidi e larvicidi. Il personale incaricato, composto da tecnici Asl, addetti della ditta Asmiu e agenti della polizia municipale, agirà in un raggio di 200 metri dall’abitazione del paziente, intervenendo anche su aree private, siepi e pozzetti.

La Chikungunya non si trasmette direttamente da persona a persona, ma esclusivamente tramite la puntura di una zanzara infetta. In Italia il vettore principale è la zanzara tigre (Aedes albopictus), ormai largamente diffusa, motivo per cui gli interventi mirano a ridurne drasticamente la densità nelle zone colpite. Durante le operazioni di disinfestazione, si raccomanda alla cittadinanza di tenere chiuse le finestre, non esporre i panni all’esterno, proteggere i giochi dei bambini e allontanare gli animali domestici dalle aree trattate.

REDAZIONE

Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1

IMMEDIAPRESS — Tue, 05 May 2026 23:03:02 +0200

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE

AMSTERDAM, May 5, 2026 /PRNewswire/ — Norgine, a leading European specialty pharmaceutical company is pleased to announce that PEDMARQSI® (sodium thiosulfate anhydrous) has been registered by the Australian Therapeutic Goods Administration (TGA) for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours.¹

Cisplatin is a widely used and important chemotherapeutic for children with solid tumours, but it carries a substantial risk of permanent hearing loss. Hearing loss in childhood can have profound and lifelong consequences, affecting speech and language development, education, social functioning and overall quality of life.2,3 PEDMARQSI® is the first and only treatment registered in Australia for the prevention of cisplatin-induced ototoxicity in paediatric patients.¹

Gus Rudolph, General Manager, Norgine, Australia, said: “The TGA registration of PEDMARQSI® marks an important milestone for children, families and healthcare professionals in Australia. Cisplatin-induced hearing loss can have lifelong consequences for young patients, and this approval provides an option specifically developed to help prevent this complication in eligible children receiving cisplatin chemotherapy. We are pleased to reach this regulatory milestone and remain focused on working with relevant stakeholders to support access for eligible patients in Australia.”

The TGA registration is based on data from two open-label, randomised Phase 3 clinical trials, SIOPEL 6² and COG ACCL0431.³

“Cisplatin‑induced hearing loss is a well‑recognised and often irreversible complication of paediatric cancer treatment, with significant long‑term implications for communication, learning and quality of life,” said Dr. David Gillen, Chief Medical Officer, Norgine. “From a clinical perspective, the ability to proactively address this risk is an important consideration when caring for children receiving cisplatin. The availability of an approved preventive option represents a meaningful development in the supportive care of paediatric oncology patients.”

Marketing authorisation for PEDMARQSI® in Australia adds to previous approvals in other territories, including Paediatric Use Marketing Authorisation (PUMA) granted by the European Medicines Agency in May 2023 and a national marketing authorisation in the United Kingdom, as well as Swissmedic approval in March 2026.4,5 This milestone further reflects Norgine’s ability to navigate regulatory pathways for rare and specialist medicines.

PEDMARQSI® is not currently included on the Pharmaceutical Benefits Scheme (PBS).Please refer to the PEDMARQSI
® Consumer Medicines Information (CMI)8 for full safety information on risks, side effects and precautions including the risk of allergic reaction, nausea and vomiting, and electrolyte imbalance (sodium, potassium, magnesium and phosphate).

About PEDMARQSI®PEDMARQSI® is a formulation of sodium thiosulfate anhydrous, specifically developed and manufactured for the prevention of cisplatin induced hearing loss in patients aged 1 month to <18 years with localised, non-metastatic solid tumours. It is the first and only preventative treatment developed for cisplatin induced ototoxicity in this patient population.1,6,7

Marketing authorisations for PEDMARQSI® were based on safety and efficacy data from two open label, randomised Phase III trials: SIOPEL 6 and COG ACCL0431.2,3

For more information on PEDMARQSI® find the CMI here: PEDMARQSI
® Consumer Medicines Information (CMI)8 or at the Therapeutic Goods Administration at https://www.tga.gov.au/ .

About NorgineNorgine is a mid-sized EU-based pharmaceutical company with 1,500 employees, generating approximately $650 million in annual sales. At Norgine, innovation drives our mission to deliver medicines that change lives. From common conditions like constipation to rare and severe diseases such as childhood cancer, we target unmet medical needs because we believe that every scientific breakthrough deserves to reach patients in need.

We use our innovative development, commercialisation and manufacturing capabilities as well as strategic partnerships to navigate complex pathways. Combined with our extensive history and deep regional expertise, this approach allows us to accelerate and expand the reach of life-changing medicines across Europe, Australia, and New Zealand.

We are guided by the trust that healthcare professionals and patients place in us and remain committed to delivering innovation that transforms lives, one patient at a time.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

References:

Job code: UK-ONC-PED-2600095

Logo – https://mma.prnewswire.com/media/2846726/5953601/Norgine_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/norgine-welcomes-tga-registration-in-australia-of-pedmarqsi-sodium-thiosulfate-anhydrous-for-the-prevention-of-cisplatin-induced-hearing-loss-in-children1-302762607.html

—

immediapress/pr-newswire

Esondazioni, allagamenti, frane e alberi caduti: giornata difficile per il maltempo in Toscana

REDAZIONE — Tue, 05 May 2026 22:30:11 +0200

FIRENZE – Il maltempo ha colpito tutta la regione dalla mattina.

Una mattinata di estrema criticità ha colpito la zona apuana, dove piogge torrenziali hanno scaricato oltre 100 millimetri d’acqua in appena tre ore. La sindaca di Carrara, Serena Arrighi, ha invitato la cittadinanza a evitare ogni spostamento non strettamente necessario. I disagi maggiori si sono registrati a Marina di Carrara, in particolare in viale Zaccagna, dove le fogne non sono riuscite a smaltire l’enorme massa d’acqua verso il mare.

L’episodio più drammatico è avvenuto a Massa, in via Bondano, a causa dell’esondazione del fosso Dalmine. L’acqua ha invaso le abitazioni e bloccato un’ambulanza diretta verso un’emergenza medica; è stato necessario l’intervento dei Vigili del Fuoco, che hanno dovuto trasportare il paziente a mano fino al mezzo di soccorso impossibilitato a proseguire. Allagamenti pesanti hanno interessato anche il sottopasso della stazione ferroviaria di Massa e numerose arterie stradali, rendendo la circolazione estremamente difficile in tutta l’area costiera. Sotto stretta osservazione il torrente Carrione, il cui livello è cresciuto rapidamente, pur rimanendo per ora sotto controllo.

Il maltempo non ha risparmiato il resto della regione.

A Prato chiuso il sottopasso della Declassata a Prato. A Firenze, i vigili del fuoco hanno utilizzato elettropompe per liberare dall’acqua i locali in via Mannelli. Si segnala inoltre il cedimento di un muro sulla collina di Marignolle e il rapido innalzamento del fiume Greve.

Un tornado si è formato nell’Empolese, fortunatamente senza causare danni al suolo, mentre trombe d’aria sono state avvistate tra Sovigliana e Cascina. Allagamenti di scantinati sono stati segnalati a Castelfiorentino e Figline Valdarno.

Un cipresso è caduto sul loggiato della pieve di San Giuliano a Settimo, fortunatamente senza ferire nessuno e senza compromettere la fruibilità della chiesa.

In serata, il presidente della Regione Eugenio Giani ha confermato che la linea temporalesca rimane attiva tra Campiglia Marittima, Poggibonsi e il Casentino. Nonostante i picchi di 110 millimetri registrati a Minucciano e Massa e i 40 caduti in un’ora a Pian di Scò, i livelli dei principali fiumi toscani restano al momento entro le soglie di riferimento.

REDAZIONE

THEON announces Q1 2026 Trading Update

IMMEDIAPRESS — Tue, 05 May 2026 22:09:52 +0200

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE

PRESS RELEASE

Bloomberg (THEON:NA) / Reuters (THEON.AS)

5 May 2026 – Theon International Plc (THEON) publishes its Q1 2026 Trading Update. The results and activity reflect another period of consistent delivery on promises, with THEON remaining highly confident in its FY 2026 Guidance and Medium-Term Targets.

Theon has entered Q2 2026, actively pursuing actively pursuing numerous opportunities across multiple areas to sustain high organic growth, in line with its Medium-Term organic growth commitment of above 15%. THEON is confident in maintaining its Book-to-Bill Ratio of above 1.0x and strong backlog, with structural growth trends and the move towards longer-term framework agreements to provide greater visibility than historically.

In parallel, inorganic growth contributes to THEON’s growth trajectory; Monday’s announcement of MERIO is the latest development, with an active pipeline of acquisitions and strategic partnerships expected to be finalized throughout the year.

Financial Summary

1Reflects a change in accounting policy to include the Group’s share of profits from core equity- accounted investees within operating profit, adopted in Q2 2025 – effective from 1 January 2025.

2Net income and EPSof Q1 2026 include the impact of the mark‑to‑market valuation of our investment in Exosens, which is classified as a financial asset measured at fair value through profit or loss.

3Defined as (Adjusted EBITDA – Capex) / Adjusted EBITDA

4 Includes net proceeds of €147.7 million from the rights issue offering completed in December 2025

Key Highlights

Financial Highlights

Operational and Strategic Highlights

Corporate Highlights

The full Q1 2026 Trading Update is available on the Company’s website and can be found here

Group Outlook

Guidance remains unchanged, and is per the below:

Christian Hadjiminas, Founder and CEO of THEON, stated: “Q1 2026 demonstrates once again the resilience, diversification and huge growth potential of our business. While order intake was softer year-on-year due to market seasonal patterns and phasing of contracts, momentum is building and strong inflow of orders is expected over the coming quarters. On our 32% revenue growth, this represented both increased product and geographic diversification, with platform products now contributing to our top line, in line with our commitment to our investors. On M&A, we remain highly active, our agreement to acquire 80% of MERIO is a strategically significant move, giving THEON a direct presence in the drone and light aerial platform segment as warfare tactics continue to evolve rapidly. Looking ahead, we will continue to advance our technological capabilities and execute on our growth strategy, progressing toward our €1 billion revenue target by 2029.”

For inquiries, please contact:

About THEON GROUP

THEON GROUP of companies develops and manufactures cutting-edge night vision and thermal imaging systems for Defense and Security applications with a global footprint. THEON GROUP started its operations in 1997 from Greece and today occupies a leading role in the sector thanks to its international presence through subsidiaries and production facilities in Greece, Cyprus, Germany, the Baltics, the United States, the Gulf States, Switzerland, Denmark, Belgium, Singapore and South Korea. THEON GROUP has more than 280,000 systems in service with Armed and Special Forces in 72 countries around the world, 26 of which are NATO countries. ΤΗΕΟΝ ΙΝΤΕRNATIONAL PLC has been listed on Euronext Amsterdam (AMS: THEON) since February 2024.www.theon.com

Attachment

—

immediapress/globenewswire

CAI Launches Next Chapter with Investment from JLL Partners

IMMEDIAPRESS — Tue, 05 May 2026 18:02:00 +0200

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE

INDIANAPOLIS, May 5, 2026 /PRNewswire/ — CAI, a professional services firm dedicated to accelerating operational readiness and excellence in life sciences and mission-critical environments, today announced that it has entered into an agreement with JLL Partners, a New York-based middle-market private equity firm focused on investing in the healthcare, industrials, and business services sectors, to support the next phase of growth for CAI.

This partnership positions CAI to expand its global footprint, invest in next-generation technologies, and enhance its service offerings to better support customers operating in complex, technically demanding, and highly regulated environments.

“Our partnership with JLL marks an important strategic milestone for our future,” said CAI CEO Sheena Dempsey. “For more than 30 years, CAI has been defined by a relentless focus on quality and a commitment to doing things the right way. That foundation has enabled us to grow into a trusted partner across the industries we serve. As we look ahead, this partnership will help us scale our impact – expanding geographically, advancing our capabilities in next-generation technologies, and continuing to deliver high-impact outcomes for our customers. JLL Partners’ investment is a vote of confidence in both the company we have built and the next-level growth we can achieve moving forward.”

Vikas Mouli, Managing Director at JLL Partners, said, “We are excited to partner with CAI at a time when the life sciences and advanced manufacturing sectors are experiencing significant investment and rapid technological advancement. CAI has built a strong reputation, borne by decades of unparalleled experience, for helping bring cutting-edge facilities online with precision and reliability. We look forward to working closely with the management team at CAI and its talented global workforce to support the company’s continued growth and innovation.”

The CAI team of more than 700 professionals operating across North America, Europe, Australia, and Asia possesses elite expertise, outstanding service, longstanding client relationships, and globally recognized performance. With JLL Partners’ financial sponsorship, CAI is uniquely positioned to continue assembling industry-leading talent, elevating them through top-tier training and exposure, and driving the industries they serve into the future.

Note: JLL Partners and CAI have entered into definitive documentation for this transaction; however, it has not yet closed and remains subject to customary regulatory approvals and other conditions.

About CAICAI is a professional services firm composed of engineering, quality, and operations experts dedicated to accelerating operational readiness and excellence in life sciences and mission-critical environments. With deep roots in CQV (commissioning, qualification, validation), CAI has evolved over the past 30 years alongside the industries it serves, helping organizations bring complex facilities, systems, and technologies online with confidence.

The elite team at CAI combines deep technical expertise with proven processes and modern tools to deliver projects on time and within budget, supporting outcomes that matter in highly regulated environments. Over three decades, CAI has embraced new modalities and guided clients through digital transformation while strengthening operational readiness. As industry demands grow, CAI strives to define the next era of agility, resilience, and operational excellence.

For more information, please visit https://caiready.com/.

About JLL PartnersJLL Partners, LLC is a middle-market private equity firm with over three decades of experience transforming businesses in the healthcare, industrials, and business services sectors. The Firm is dedicated to partnering with companies that it believes it can help build into market leaders through a combination of strategic mergers and acquisitions, organic growth initiatives, and operational enhancements. The JLL Partners team is comprised of seasoned investment professionals and operating partners who are focused on driving long-term value creation across its portfolio. Since its founding in 1988, JLL Partners has invested approximately $8 billion of equity capital with 61 platform investments.

For more information, please visit www.jllpartners.com.

Logo – https://mma.prnewswire.com/media/2972509/CAI_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/cai-launches-next-chapter-with-investment-from-jll-partners-302762777.html

—

immediapress/pr-newswire

Massa, la partita finisce ma la violenza continua: arrestati due ultras della Massese

REDAZIONE — Tue, 05 May 2026 17:15:06 +0200

MASSA – Due ultras della Massese sono stati arrestati dalla Digos nella mattinata di lunedì 5 maggio per i disordini scoppiati al termine del playout contro la Larcianese, disputato domenica (3 maggio). I due, italiani di 23 e 34 anni, sono ritenuti responsabili di aver partecipato al lancio di oggetti contro le forze dell’ordine al termine dell’incontro e sono accusati di violenza a pubblico ufficiale in concorso con altri soggetti ancora in corso di identificazione.

Come sono stati identificati

Al termine della partita un gruppo di tifosi aveva aggredito le forze dell’ordine con un fitto lancio di oggetti. Gli investigatori della Digos hanno immediatamente avviato l’analisi delle immagini raccolte dalla polizia scientifica, riuscendo a identificare in tempi rapidi i due presunti responsabili. Entrambi sono riconducibili al gruppo ultras Legione Cybea. L’arresto è avvenuto in virtù della norma che consente il fermo in flagranza differita entro 48 ore per i reati commessi durante le manifestazioni sportive.

Le conseguenze

I due tifosi sono stati messi a disposizione dell’autorità giudiziaria in attesa della convalida dell’arresto. Nei loro confronti sarà inoltre avviata la procedura per l’emissione del Daspo da parte del questore di Massa Carrara. Le indagini proseguono per identificare gli altri partecipanti agli scontri.

REDAZIONE

GoodWe introduces Warm Home All-in-One Solution to UK while biggest home upgrade plan in British history rolls out

IMMEDIAPRESS — Tue, 05 May 2026 16:45:00 +0200

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE

LONDON, May 5, 2026 /PRNewswire/ — GoodWe presented their Warm Home All-in-One Solution at a launch event in London, welcoming nearly 150 industry leaders and market experts for an evening of insights and exchange. The solution integrates solar, storage, EV charging, heating and smart energy management into one unified system, helping homeowners to access clean energy more easily while reducing energy costs.

“The UK Warm Homes Plan sets a clear direction: to transform households into active energy units. This means homes are no longer just consuming energy but also producing and managing it. This is what we call Energy Prosumers.” shared by Daniel Huang, Founder & CEO of GoodWe, in his keynote speech.

PV + Storage in Matured Market with Favourable Conditions

“Demand for residential solar in the UK is growing”, said Markus A.W. Hoehner, Founder & CEO of the EUPD Group. “The market is structurally aligned for accelerated uptake of solar PV and battery storage. We see this trend being reinforced by installer behaviour, with nearly all providers offering bundled PV and storage solutions as a standard residential package in the UK.”

The UK government announced the £15 billion Warm Homes Plan in January 2026, targeting upgrades to up to 5 million homes by 2030. Approximately £5 billion is allocated to fully funded upgrade packages for low-income households, while a combination of subsidised zero- and low-interest loans and investment mechanisms will support broader household adoption of solar PV, batteries, and heat pumps.

GoodWe’s Warm Home All-in-One Solution

With their Warm Home All-in-One Solution including Photovoltaic Building Materials (PVBM), inverter and storage system such as ESA series, EV charger, heat pump, and smart management, GoodWe addresses the key needs of the UK residential solar market. The system allows for a 70% self-consumption rate, substantially reducing the energy bill as well as emissions.

To adapt to different local housing conditions, the company also offers a compact micro-storage solution for social housing and houses with limited space, enabling them to access clean energy with minimal effort.

GoodWe introduced their “One System, One Supplier, One Service” approach during the event. With one brand behind the entire solution, this means a simpler installation process and fewer compatibility concerns for installers. For homeowners, it means a smoother experience and a more reliable system. In the meantime, service becomes clear and standardised.

ESA Energy Storage System at the core

The center of this solution is the ESA All-in-One energy storage system, combining a solar PV inverter with modular batteries and an intelligent energy management system. Designed under GoodWe’s “4S System” concept: silent, smart, secure, and simple, the ESA series is designed to deliver both performance and user-centric experience.

With noise as a major concern for the integration of technology in residential spaces, GoodWe pointed out that even their 3-phase ESA models manage to run as low as 30dB* (*5~8kW｜at 25°C ambient) operating noise. This is achieved through custom low-noise fans, real-time adaptation to operating conditions and ultra silent mode that can be activated by the user.

Industry’s First White Paper on PV + ESS Acoustic Performance

During the event, GoodWe, in collaboration with TÜV Rheinland, released a white paper on PV and ESS acoustic performance, which provides technical insights into noise optimisation in residential adoption and beyond. As the industry’s first white paper dedicated to noise reduction in PV and energy storage systems, it aims to advance low-noise standards across the sector and improve user experience.

“Clearer industry standards around noise are needed for residential energy storage systems. This would help define acceptable noise thresholds and ensure that systems are designed to minimise disturbances in densely populated areas,” shared Aditya Lyer, Key Account Manager at TÜV Rheinland, during the event.

Compatibility with Leading Smart Tariffs

At the launch event in London, GoodWe and Kraken held a signing ceremony honouring their new partnership. The smart features of the ESA Series devices also include Virtual Power Plant (VPP) and Energy Management System (EMS) compatibility. In the UK market, GoodWe have successfully completed system compatibility and integration with Kraken, the technology platform behind Octopus Energy’s smart tariffs.

Photo – https://mma.prnewswire.com/media/2972860/GoodWe_Warm_Home_All_in_One.jpg

View original content:https://www.prnewswire.co.uk/news-releases/goodwe-introduces-warm-home-all-in-one-solution-to-uk-while-biggest-home-upgrade-plan-in-british-history-rolls-out-302762816.html

—

immediapress

Cognex lancia il sistema di visione artificiale integrato ad alte prestazioni, basato su tecnologia Qualcomm

IMMEDIAPRESS — Tue, 05 May 2026 15:02:19 +0200

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE

In-Sight® 3900 definisce un nuovo standard per l’ispezione ad alta velocità e precisione in ambiente edge, senza la necessità di un PC esterno

NATICK, Massachusetts, 5 maggio 2026 /PRNewswire/ — Cognex Corporation (NASDAQ: CGNX), leader tecnologico globale nella visione artificiale industriale, ha annunciato oggi il lancio del sistema di visione In-Sight® 3900. Basato su una nuova generazione di tecnologia di visione AI integrata di Cognex, e supportato dalle piattaforme Qualcomm Dragonwing™, In-Sight 3900 è un sistema di visione completamente integrato che offre velocità, precisione e risoluzione leader del settore in edge computing, consentendo ai produttori di eseguire ispezioni complesse senza sacrificare la produttività o la semplicità.

“In-Sight 3900 rappresenta un importante passo avanti in termini di ciò che la visione AI integrata può offrire nel reparto produzione”, ha affermato Matt Moschner, presidente e CEO di Cognex. “I produttori non devono più scegliere tra profondità di ispezione e velocità di linea. Abbiamo realizzato un sistema che offre entrambe le cose, con l’affidabilità e la semplicità per cui Cognex è rinomata”.

Visione AI ad alta velocità, senza compromessiIn-Sight 3900 elimina il tradizionale compromesso tra profondità di ispezione e velocità di linea imposto dai sistemi di visione tradizionali. Grazie alla combinazione di Edge AI, Advanced AI e strumenti di visione basati su regole e sviluppati da Cognex con un sistema di elaborazione integrato ad alte prestazioni, il sistema consente ispezioni deterministiche in tempo reale alla massima velocità di linea, supportando applicazioni di nuova generazione nei settori dell’imballaggio, automobilistico, elettronico e dei beni di consumo.

“Le nostre linee di confezionamento funzionano a velocità estremamente elevate, il che in passato ci limitava all’uso di strumenti OCR tradizionali”, ha affermato Andrea Sabbadini, responsabile tecnico presso Fuji Seal. “In-Sight 3900 ci consente ora di implementare gli strumenti Edge AI Read di Cognex alla massima velocità di produzione senza compromettere la produttività. Il risultato è un processo di ispezione più rigoroso, più rapido da configurare e più facile da gestire su tutte le nostre linee”.

Funzionalità principali

Progettato per l’IA avanzata all’edgeIn-Sight 3900 si basa sull’architettura di IA integrata di ultima generazione di Cognex, e incorpora un processore di IA dedicato ad alte prestazioni per un processo decisionale veloce e deterministico direttamente all’edge. La piattaforma supporta:

“Cognex ha ampliato i confini di ciò che la visione AI integrata può offrire all’edge”, ha affermato Shyam Krishnamurthy, vicepresidente senior di Qualcomm. “Siamo orgogliosi di supportare questa innovazione con la tecnologia Qualcomm, e attendiamo con interesse di scoprire ciò che questa collaborazione continuerà a offrire ai produttori che eseguono ispezioni complesse alla massima velocità di produzione”.

Parte di un ecosistema di visione AI dal cloud‑all’‑edgeSe abbinato a Cognex OneVision™, In-Sight 3900 diventa parte di un ecosistema di visione AI scalabile, dal cloud all’edge. OneVision semplifica lo sviluppo dei modelli, la collaborazione tra siti e l’implementazione su diversi dispositivi, consentendo ai produttori di addestrare i modelli di IA a livello centrale ed eseguire al contempo ispezioni a livello locale, alla velocità di produzione.

Informazioni su Cognex CorporationDa oltre 40 anni, Cognex rende accessibile la visione artificiale avanzata, aprendo la strada alle aziende di produzione e distribuzione affinché diventino più veloci, intelligenti ed efficienti grazie all’automazione. La tecnologia innovativa dei nostri sensori e sistemi di visione risolve le sfide critiche di produzione e distribuzione, fornendo prestazioni senza pari per settori che vanno dall’automotive all’elettronica di consumo fino ai beni confezionati. Grazie a una attenzione di lunga data rivolta all’IA, Cognex rende questi strumenti più potenti e facili da implementare, aiutando fabbriche e magazzini a migliorare la qualità e massimizzare l’efficienza senza la necessità di competenze tecniche altamente specializzate. La nostra sede centrale si trova vicino a Boston, negli Stati Uniti, con sedi in oltre 30 Paesi e più di 30.000 clienti in tutto il mondo. Per saperne di più, visitare il sito cognex.com.

I prodotti a marchio Qualcomm sono prodotti di Qualcomm Technologies, Inc.

Contatto per i media:Liz Bradley – Responsabile della comunicazioneCognex Corporationpr@cognex.com

Contatto per le relazioni con gli investitori:Greer Aviv – Responsabile delle relazioni con gli investitoriCognex Corporationir@cognex.com

Foto – https://mma.prnewswire.com/media/2971079/Cognex_In_Sight_3900_Vision_System.jpgLogo – https://mma.prnewswire.com/media/2310647/Cognex_Logo.jpg

View original content:https://www.prnewswire.com/it/comunicati-stampa/cognex-lancia-il-sistema-di-visione-artificiale-integrato-ad-alte-prestazioni-basato-su-tecnologia-qualcomm-302760801.html

—

immediapress/pr-newswire

Viralgen Partners with Elaaj Bio to Advance Gene Therapy Program for CDKL5 Deﬁciency Disorder

IMMEDIAPRESS — Tue, 05 May 2026 14:32:10 +0200

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE

Collaboration leverages AAV manufacturing expertise to advance a preclinical-stage gene therapy program for a rare pediatric neurological disorder.

SAN SEBASTIÁN, Spain and LONDON, May 5, 2026 /PRNewswire/ — Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, announced today a partnership with Elaaj Bio, a biotechnology company focused on development of transformative treatments for CDKL5 Deﬁciency Disorder (CDD). Elaaj Bio is a wholly owned subsidiary of the Loulou Foundation, a private non-proﬁt foundation dedicated to the development and research of therapeutics for CDD. The collaboration, to advance an investigational CDKL5 gene therapy, brings together complementary expertise across development and manufacturing services for adeno-associated virus (AAV) vectors to support advancement of the program toward clinical development.

As part of the collaboration, Viralgen will leverage its expertise in AAV vector manufacturing to support key development activities, including process development and optimization, manufacturing across multiple scales, and analytical characterization and quality control. Initial development work has been successfully completed, demonstrating technical feasibility of the manufacturing approach, and ongoing activities are focused on process scale-up, including the preparation of larger-scale batches.

“Collaborations like this are essential to advancing complex gene therapy programs, particularly in rare pediatric diseases where the need for new therapies and innovations remains high,” said Jimmy Vanhove, Chief Executive Officer at Viralgen. “By working with Elaaj Bio and the Loulou Foundation, we’re uniting complementary strengths in development and manufacturing to help accelerate ELJ-101 toward clinical development.”

CDKL5 Deﬁciency Disorder (CDD) is a rare and severe developmental and epileptic encephalopathy caused by alterations in the CDKL5 gene. The condition is characterized by early-onset seizures and signiﬁcant neurodevelopmental impairment, with a profound impact on affected individuals and their families. The

investigational gene therapy program is being developed to target the underlying genetic cause of the disease.

“Elaaj Bio and the Loulou Foundation are mission-driven: everything we do is focused on ﬁnding treatments for CDD,” said Russ Addis, Chief of Pipeline Strategy and Head of Genetic Medicine at the Loulou Foundation. “The Viralgen team have embraced that mission; we have great hopes that this collaboration will result in an effective gene therapy that treats the underlying cause of CDKL5 Deﬁciency.”

The teams plan to initiate the ﬁrst clinical trial for this program, ELJ-101, in early 2027. Current efforts are focused on scaling manufacturing processes to support future clinical development.

About Viralgen:

Viralgen is a leading Contract Development and Manufacturing Organization (CDMO) specializing exclusively in adeno-associated virus (AAV)-based gene therapies. Founded in 2017 as a subsidiary of AskBio, Inc. within the Bayer AG group, Viralgen delivers end-to-end support from early development to large-scale commercial manufacturing. Leveraging their proprietary Pro10™ suspension cell line and Aava™ manufacturing platform, Viralgen achieves industry-leading, high-yield, scalable manufacturing across all AAV serotypes. Located in San Sebastian, Spain, its state-of-the-art facility features three cGMP suites with 2,000-liter capacities each, certiﬁed by the AEMPS/EMA, and integrates services including plasmid production, process optimization, ﬁll-ﬁnish, and in-house QC testing. With over 1,500 AAV batches produced, Viralgen provides reliable, efficient solutions bringing life-changing gene therapies to patients with greater speed and consistency. Learn more at viralgen.com and follow us on LinkedIn.

About Elaaj Bio and the Loulou Foundation:

Elaaj Bio is a wholly owned subsidiary of the Loulou Foundation, a private non-proﬁt UK foundation dedicated to advancing research into the understanding and development of therapeutics for CDKL5 deﬁciency disorder. The Foundation funds research projects at leading universities and institutes in the US and Europe, with a

total of 31 separate projects in 41 labs at 30 different institutions so far, enabling the

focused research of over 120 scientists.

The Loulou Foundation also hosts the CDKL5 Forum, the annual conference which has become the ﬂagship meeting for CDKL5 deﬁciency disorder basic and clinical science. Learn more at http://www.louloufoundation.org and http://www.elaajbio.com.

This press release contains forward-looking statements regarding the development of an investigational gene therapy program. These statements are subject to risks and uncertainties, including those related to research and development, manufacturing, and regulatory processes. The investigational therapy described herein has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.

Photo – https://mma.prnewswire.com/media/2971842/Viralgen_scientist.jpg Logo – https://mma.prnewswire.com/media/2592385/5951250/Viralgen__logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/viralgen-partners-with-elaaj-bio-to-advance-gene-therapy-program-for-cdkl5-deciency-disorder-302761295.html

—

immediapress/pr-newswire

YASH Technologies Recognized as a Disruptor in Avasant’s Data Center Managed Services 2025-2026 RadarView™

IMMEDIAPRESS — Tue, 05 May 2026 14:04:03 +0200

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE

This recognition underlines YASH’s AI-first approach to modern infrastructure management and its expanding global delivery footprint.

CHICAGO, May 5, 2026 /PRNewswire/ — YASH Technologies, a global technology services and solutions provider, has been recognized as a Disruptor in Avasant’s Data Center Managed Services 2025–2026 RadarView™. This achievement places YASH among 27 providers worldwide who are rethinking managed services with innovative, AI-led approaches. It is a commendation given to those who push boundaries and introduce fresh methods that energize the industry.

Rakesh Kumar Jain, Global Head – Cloud & Infrastructure Services at YASH Technologies, said: “Being recognized as a Disruptor by Avasant highlights how we are redefining managed services. Enterprises today demand incremental efficiency; they need resilient, secure, and scalable infrastructure that fuels transformation. YASH delivers this through AI-enabled, automation-first operations governed by experience-level agreements (XLAs) and disciplined FinOps. By embedding predictive intelligence and deep automation across the data center stack, we help our clients cut costs, prevent disruptions before they occur, and accelerate digital growth to ensure greater enterprise agility.”

Avasant’s RadarView™ highlights the industry’s shift toward AI-enabled operations that improve resilience, optimize costs, and support hybrid cloud environments. Enterprises are increasingly prioritizing predictive operations, automation, and real-time visibility to manage the growing complexity of their infrastructure while meeting performance, security, and compliance expectations.

In its assessment, Gaurav Dewan, Research Director at Avasant, mentioned: “YASH Technologies aligns strongly with this shift through its AI-driven data center managed services, underpinned by AIOps-led monitoring, predictive analytics, and automation across compute, storage, and virtualization layers. Its investments in generative AI-enabled capabilities for anomaly detection, predictive failure prevention, and agentic AI for service desk operations enable enterprises to move from reactive infrastructure management to proactive, insight-led operations. Its strategic partnerships with Equinix for power management and cooling services and with Dell for AI-driven capacity planning further strengthen its end-to-end value proposition. This focused alignment of AI-enabled operations and ecosystem-led delivery reinforces YASH Technologies’ position as a Disruptor in Avasant’s Data Center Managed Services 2025–2026 RadarView™.”

About YASH Technologies

YASH Technologies helps enterprises reimagine what’s possible and accelerate transformation with an AI-first, consultative, value-centric approach. As a global technology integrator, YASH brings together strategic advisory, deep industry expertise, and innovative accelerators to deliver business outcomes at scale. By embedding AI across frameworks and services, we enable organizations to modernize applications, unlock value from business data, optimize infrastructure, and create secure, intuitive experiences for their employees, customers, and partners. Headquartered in the U.S. and with an extensive network of global delivery centers, YASH serves clients across six continents. The company is appraised at CMMI-DEV V2.0 Level 5 and is certified under ISO 9001:2015 and ISO 27001:2013. Learn more at www.yash.com.

Photo: https://mma.prnewswire.com/media/2972712/Avasant_Data_Center_YASH_Technologies.jpgLogo: https://mma.prnewswire.com/media/1245393/5248703/YASH_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/yash-technologies-recognized-as-a-disruptor-in-avasants-data-center-managed-services-20252026-radarview-302762629.html

—

immediapress/pr-newswire

BYD sceglie bolttech come partner strategico per la sua soluzione di assicurazione integrata

IMMEDIAPRESS — Tue, 05 May 2026 12:07:37 +0200

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE

La partnership pluriennale si concentra inizialmente su cinque mercati europei

LONDRA, 5 maggio 2026 /PRNewswire/ — BYD, leader mondiale nella produzione di veicoli a energia alternativa, ha scelto bolttech, società globale specializzata in insurtech, come partner strategico di riferimento per le sue soluzioni assicurative integrate da inserire nei principali mercati europei. La partnership è già stata avviata nel Regno Unito e proseguirà in Italia, Francia, Germania e Spagna nel corso di quest’anno.

bolttech amplierà la sua pluripremiata piattaforma di assicurazione integrata basata sull’intelligenza artificiale per offrire ai clienti BYD pacchetti assicurativi dinamici e personalizzati per veicoli elettrici, proposti da una selezione di compagnie assicurative. I servizi integrati saranno disponibili online e presso i concessionari, con opzioni di copertura accessibili sulla piattaforma bolttech durante il processo di acquisto e finanziamento del veicolo.

Stella Li, vicepresidente esecutivo di BYD, ha dichiarato: “Siamo entusiasti di collaborare con bolttech come nostro partner insurtech in Europa, così da poter trasformare analisi e dati in valore concreto per i clienti BYD”. Grazie a questa partnership, i clienti potranno accedere più facilmente a un’assicurazione auto perfettamente integrata nel processo di acquisto del veicolo, garantendo loro una copertura completa per i veicoli elettrici fin dal momento in cui tornano a casa con la loro auto.

Rob Schimek, amministratore delegato del gruppo bolttech, ha dichiarato: “Siamo onorati di affiancare BYD, leader mondiale nel settore dei veicoli elettrici, nella sua ambiziosa missione volta a promuovere un futuro tecnologico più sostenibile. Insieme, forniremo alle compagnie assicurative dati più completi sui veicoli e informazioni approfondite sui rischi, consentendo una determinazione dei prezzi più accurata e migliori opzioni assicurative per i conducenti BYD”.

La partnership andrà oltre la preventivazione digitale e l’emissione delle polizze. Grazie a questa collaborazione, BYD e bolttech forniranno alle compagnie assicurative l’accesso necessario a informazioni dettagliate sulla sicurezza e a dati proprietari sui veicoli, consentendo agli agenti assicuratori di valutare meglio i rischi e sviluppare prodotti più competitivi per l’ecosistema BYD.

BYD è l’unica casa automobilistica che produce internamente le proprie batterie, i propri motori elettrici e i propri sistemi di propulsione. Recentemente ha lanciato la “Blade Battery” di seconda generazione, che offre una ricarica FLASH veloce quanto il rifornimento di carburante, stabilendo nuovi standard in termini di sicurezza e durata. La piattaforma di bolttech contribuirà a trasmettere questi progressi tecnici in tempo reale agli assicuratori, consentendo una copertura più intelligente e specifica per i veicoli elettrici.

View original content:https://www.prnewswire.com/it/comunicati-stampa/byd-sceglie-bolttech-come-partner-strategico-per-la-sua-soluzione-di-assicurazione-integrata-302762525.html

—

immediapress/pr-newswire

Allarme nei pronto soccorso toscani: turni massacranti e indennità negate, la Cisl minaccia la mobilitazione

REDAZIONE — Tue, 05 May 2026 11:20:50 +0200

FIRENZE – La tenuta del sistema sanitario della Toscana vacilla sotto il peso di una crisi che, per i reparti di emergenza-urgenza, ha ormai assunto i contorni di un vero e proprio cedimento strutturale. A lanciare l’allarme è la Cisl Funzione Pubblica regionale, che punta il dito contro le condizioni lavorative insostenibili e il mancato riconoscimento economico per medici, infermieri, operatori socio-sanitari e tecnici.

Al centro della denuncia c’è il trattamento salariale riservato a chi opera in prima linea. L’accusa mossa all’Assessorato alla Sanità è precisa: la Regione starebbe di fatto negando le indennità economiche stabilite dal contratto nazionale di categoria. Le attuali retribuzioni aggiuntive vengono definite dal sindacato come delle semplici ‘briciole’, del tutto inidonee a compensare l’enorme carico di responsabilità, lo stress psicofisico estremo e i crescenti rischi a cui il personale è sottoposto.

L’effetto diretto di questa situazione, unito al cronico sovraffollamento dei reparti e a turnazioni che mettono a repentaglio il fisiologico diritto al riposo, è una progressiva fuga dei professionisti. Sempre più lavoratori, infatti, scelgono di abbandonare le strutture pubbliche toscane per trasferirsi in altre regioni o passare al settore privato. Questo esodo innesca un pericoloso circolo vizioso: chi resta deve farsi carico dei vuoti in organico, accumulando ulteriore stanchezza e minando la sicurezza complessiva. Un quadro già critico, esacerbato dalla continua escalation di aggressioni fisiche e verbali subite dai sanitari, sempre più esposti al rischio di ‘burnout’.

Per scongiurare il blocco totale del sistema, l’organizzazione sindacale ha tracciato una linea d’azione basata su tre richieste ineludibili. In primo luogo, un incremento corposo dei fondi destinati al personale dell’emergenza, proporzionato alla reale difficoltà delle mansioni. In secondo luogo, la copertura tempestiva delle posizioni vacanti, passaggio obbligato per ripristinare una corretta e umana rotazione dei turni. Infine, l’introduzione di misure concrete per arginare le violenze nei presidi sanitari.

Il segretario generale della Cisl-Fp Toscana, Andrea Nerini, ha chiarito che il tempo degli annunci sui social media è finito, chiedendo alle istituzioni risposte tangibili e prospettando azioni incisive in caso di immobilità: “Non resteremo a guardare mentre il diritto alla salute e la dignità del lavoro vengono calpestati. Siamo pronti a mettere in atto ogni forma di mobilitazione se dall’Assessorato non arriveranno segnali concreti e immediati”.

REDAZIONE

SOFTSWISS Launches Tech Race Summit 2026 to Address High-Load Infrastructure Challenges

IMMEDIAPRESS — Tue, 05 May 2026 10:34:15 +0200

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE

GZIRA, Malta, May 5, 2026 /PRNewswire/ — SOFTSWISS is launching Tech Race Summit 2026, a new high-load technology conference dedicated to solving the engineering and infrastructure challenges in the iGaming industry. The event takes place on 10 September 2026 in Warsaw, Poland. Confirmed speakers include representatives from Amazon, Gcore, and Fastly, alongside technology leaders from iGaming and other high-load sectors.

The summit responds to a clear gap in the current conference landscape. As the iGaming industry grows in complexity, its infrastructure demands increasingly mirror those of other high-volume sectors. Yet most industry events remain oriented toward business development and commercial networking. Engineers, CTOs, product leaders, and technology decision-makers who actually build and run these systems have had no dedicated forum for in-depth technical discussion, comparing approaches, and learning from peers facing the same pressures from different angles. Tech Race Summit is that space.

The summit is built around cross-industry panel discussions. These sessions place knowledge exchange at the centre of the agenda, bringing together iGaming technology leaders and specialists from fields such as fintech, cybersecurity, cloud, and others.

“The iGaming industry has grown to the level of technical complexity that demands its own conversation – and its own community,” said Sergey Kastukevich, Chief Technology Officer at SOFTSWISS. “What we kept hearing from CTOs, engineers, and tech leaders across the industry was that they wanted a space to go deep: real architecture discussions, honest post-mortems, hard-won knowledge from people solving similar problems at scale. That space didn’t exist, so we built it.”

The summit will feature three tracks – the Main Track, the Engineering Track, and the VIP Track – scaling from open keynotes and panels down to small-group roundtables and exclusive sessions for decision-makers. Sessions span high-load systems architecture, AI implementation at scale, cybersecurity, cloud and edge infrastructure, platform strategy, and the technology decisions that are shaping today’s world.

The early bird tickets are available now at the Tech Race Summit website.

About SOFTSWISS

SOFTSWISS is a global tech company, supplying award-winning software solutions for iGaming since 2009. Supported by a team of over 2,000 experts, SOFTSWISS serves more than 1,000 global brands.

Photo – https://mma.prnewswire.com/media/2970211/SOFTSWISS.jpgLogo – https://mma.prnewswire.com/media/2866432/5947419/SOFTSWISS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/softswiss-launches-tech-race-summit-2026-to-address-high-load-infrastructure-challenges-302762445.html

—

immediapress/pr-newswire

Geotab integrates Polestar vehicles into its OEM telematics network

IMMEDIAPRESS — Tue, 05 May 2026 10:01:05 +0200

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE

Fleet operators across North America, Europe, and APAC can now access Polestar vehicle data directly in MyGeotab — no aftermarket hardware required.

LONDON, UK, May 5, 2026 /PRNewswire/ — Geotab, a global leader in connected vehicle and asset management solutions, today announced the integration of Polestar vehicles into its OEM telematics network, giving commercial fleet operators seamless access to Polestar data within MyGeotab from day one — with no aftermarket hardware installation required. The integration is available globally across North America, Europe, and Asia Pacific, supporting all Polestar models.

Developed in collaboration with Geotab, among other telematics service providers, Polestar Fleet Telematics integrates directly into MyGeotab. The Geotab integration enables fleet managers to manage Polestar vehicles alongside all other makes and models on a single unified platform — without fitting additional devices.

Connected vehicle data where it matters most

Through Polestar Fleet Telematics, fleet operators gain near-real-time access to a comprehensive dataset — covering EV battery and charging status, location, tyre information, vehicle security, maintenance alerts, and climate data — flowing directly from Polestar’s connected vehicle architecture into MyGeotab, with no physical installation required.

This breadth of data enables fleet managers to move from reactive to proactive operations — scheduling maintenance before failures occur, optimising charge planning across depots, and maintaining duty-of-care oversight across the entire fleet.

Supporting Europe’s Mixed-Fleet Reality

OEM-embedded telematics removes the need for aftermarket device installation across mixed-manufacturer fleets, reducing logistical overhead and supporting compliance with works council and GDPR requirements — a critical consideration for European fleet operators.

“Polestar Fleet Telematics combines sustainability with intelligence, integrating seamlessly with Geotab to deliver these capabilities directly into the platforms fleet operators trust. Continuous data visibility enables more efficient and informed fleet operations, from day-to-day management to long-term planning. By leveraging Polestar vehicles’ embedded connectivity, fleet managers can make smarter, data-driven decisions — without adding hardware or complexity to their operations.” said Emma Knapp, Manager of Global Key Accounts at Polestar.

Polestar joins an OEM telematics network that already spans over 80% of leading global vehicle manufacturers by fleet market share, including BMW Group, Ford, Stellantis, Volkswagen Group, and Volvo Cars. For fleet operators already using MyGeotab, Polestar vehicles can be connected and deliver data without any additional hardware or installation.

“OEM-embedded telematics represents a change in how fleet data reaches the platform — and Polestar’s connected vehicle architecture makes this integration particularly well-suited for markets that are seriously considering transitioning to electric vehicles.” said Christoph Ludewig, Vice President OEM Global at Geotab. “Fleet operators managing mixed EV and internal combustion engine fleets no longer need separate tools or hardware for each vehicle type. Polestar data flows directly into MyGeotab alongside every other vehicle in the fleet — giving operators the consolidated visibility they need to drive efficiency, support duty of care, and manage their EV transition with confidence.”

Global Availability

The integration is available now across North America, Europe, and Asia Pacific, supporting all Polestar models. Fleet managers can activate the service via the Geotab Marketplace or by contacting their Geotab representative.

About Polestar

Polestar (Nasdaq: PSNY) is the Swedish electric performance car brand with a focus on uncompromised design and innovation, and the ambition to accelerate the change towards a sustainable future. Headquartered in Gothenburg, Sweden, its cars are available in 28 markets globally across North America, Europe and Asia Pacific.

Polestar has four models in its line-up: Polestar 2, Polestar 3, Polestar 4, and Polestar 5. Planned models include the Polestar 7 compact SUV (to be introduced in 2028) and the Polestar 6 roadster. With its vehicles currently manufactured on two continents, North America and Asia, Polestar plans to diversify its manufacturing footprint further, with production of Polestar 7 planned in Europe.

Polestar has an unwavering commitment to sustainability and has set an ambitious roadmap to reach its climate targets: halve greenhouse gas emissions by 2030 per-vehicle-sold and become climate-neutral across its value chain by 2040. Polestar’s comprehensive sustainability strategy covers the four areas of Climate, Transparency, Circularity, and Inclusion.

About Geotab

Geotab is a global leader in connected vehicle and asset management solutions, with headquarters in Oakville, Ontario and Atlanta, Georgia. Our mission is to make the world safer, more efficient, and sustainable. We leverage advanced data analytics and AI to transform fleet performance and operations, reducing cost and driving efficiency. Backed by top data scientists and engineers, we serve approximately 100,000 global customers, processing 100 billion data points daily from more than 5 million vehicle subscriptions. Geotab is trusted by Fortune 500 organisations, mid-sized fleets, and the largest public sector fleets in the world, including the US Federal government. Committed to data security and privacy, we hold FIPS 140-3 and FedRAMP authorisations. Our open platform, ecosystem of outstanding partners, and Geotab Marketplace deliver hundreds of fleet-ready third-party solutions. This year, we’re celebrating 25 years of innovation. Learn more at www.geotab.com/uk and follow us on LinkedIn or visit our blog.

GEOTAB and GEOTAB MARKETPLACE are registered trademarks of Geotab Inc. in Canada, the United States and/or other countries.

Media Contact: Geotab Contact, Romina Dashghachian, Strategic Communications Lead, EMEA, pr@geotab.com

Photo – https://mma.prnewswire.com/media/2972188/Geotab_Inc__Geotab_integrates_Polestar_vehicles_into_its_OEM_tel.jpg Logo – https://mma.prnewswire.com/media/2972187/Geotab_Inc__Geotab_integrates_Polestar_vehicles_into_its_OEM_tel.jpg

View original content:https://www.prnewswire.co.uk/news-releases/geotab-integrates-polestar-vehicles-into-its-oem-telematics-network-302761910.html

—

immediapress/pr-newswire

Quasi 2400 posti per 400 progetti con il Servizio Civile Regionale

REDAZIONE — Tue, 05 May 2026 08:03:47 +0200

FIRENZE – Una opportunità importante per 2396 giovani, residenti, domiciliati o soggiornanti in Toscana, che verranno selezionati per partecipare ai progetti di Servizio civile regionale.
Il bando è aperto ed è rivolto a ragazzi e ragazze tra i 18 e i 29 anni, disoccupati/e, inattivi/e, o studentesse/studenti che potranno scegliere tra le tante esperienze proposte. L’offerta è molto articolata, con 399 progetti proposti in totale, che abbracciano i più vari ambiti e territori: dal sociale, alla cultura, fino ai servizi.

La durata è di dodici mesi. Alle ragazze e ai ragazzi avviati al servizio civile regionale spetta un assegno mensile pari a 507 euro quale contributo mensile per lo svolgimento del servizio.
Il bando è finanziato dal Fondo Sociale Europeo plus (Fse+) 2021-2027, in particolare con le risorse assegnate alla priorità Occupazione giovanile e rientra nell’ambito di GiovaniSì, il progetto della Regione Toscana per l’autonomia dei giovani.

“L’apertura del nuovo bando per il servizio civile regionale rappresenta un passo significativo nel nostro impegno a favore dell’autonomia, della crescita e della partecipazione attiva delle giovani generazioni toscane – ha detto il presidente Giani – Oggi possiamo annunciare con grande soddisfazione che questa opportunità è aperta per quasi 2400 ragazze e ragazzi. Il contributo mensile rappresenta un supporto importante per consentire a tutti di partecipare, con il duplice obiettivo di progredire nel proprio percorso di formazione e lavoro ed essere utili alla nostra comunità attraverso il supporto all’attività di tanti enti e associazioni storiche”.

“Sono 2396 le ragazze e i ragazzi che potranno partecipare al nostro servizio civile regionale, un’opportunità davvero preziosa che siamo veramente felici e orgogliosi di mettere ancora una volta a disposizione di ragazze e ragazzi – ha detto l’assessora con delega a istruzione e servizio civile Alessandra Nardini – Qui in Toscana si potrà dunque contare non solo sul servizio civile universale messo in campo a livello nazionale, ma anche su progetti di servizio civile regionale che come Regione finanziamo. Voglio ringraziare tutti gli enti che hanno deciso di presentare i progetti, di cui quelli ammessi a finanziamento sono 399 e fanno riferimento a vari ambiti di intervento. Abbiamo scelto, con grande convinzione, di finanziare ancora una volta il servizio civile regionale perché ne riconosciamo il grande valore: un’esperienza formativa e, soprattutto, un’esperienza di cittadinanza attiva, che consente a ragazze e ragazzi di dedicare un periodo della propria vita a progetti di utilità sociale sul territorio, educandole ed educandoli alla solidarietà, al contrasto di ogni forma di discriminazione e alla pace. Oggi abbiamo ancora più bisogno di esperienze di questo tipo, anche alla luce del drammatico scenario internazionale che purtroppo stiamo vivendo“.

Sarà l’ente destinatario della domanda attraverso una commissione appositamente nominata a valutare l’idoneità e ad effettuare la selezione.

Le domande potranno essere presentate fino alle 12 del 10 giugno soltanto on line, mediante accesso accreditato alla piattaforma web.

Maggiori dettagli sul bando anche sul sito giovanisi.it.

REDAZIONE

FutureLife becomes first European fertility network to adopt an end-to-end AI fertility platform, in partnership with Alife Health

IMMEDIAPRESS — Tue, 05 May 2026 08:01:35 +0200

COMUNICATO STAMPA – CONTENUTO PROMOZIONALE

Network-wide partnership with Alife Health brings a comprehensive AI platform for fertility care, including CE-marked Embryo Predict™, to clinics across 16 countries

SAN FRANCISCO and PRAGUE, May 5, 2026 /PRNewswire/ — FutureLife Group, one of the major pan-European providers of fertility, IVF and genetics services, today announced a network-wide partnership with Alife Health to adopt Alife’s comprehensive AI platform for end-to-end clinical decision support across its clinic network. The partnership includes deployment of Embryo Predict™, Alife’s CE-marked AI tool to aid in the assessment of blastocysts for transfer decisions. The agreement positions FutureLife as the first large-scale European fertility network to make an institutional commitment to a comprehensive, multi-tool AI platform and the most extensive adoption of its kind on the continent. The partnership follows a successful multi-clinic pilot and expands AI-assisted care across FutureLife’s full network.

The platform supports clinicians and patients throughout the IVF process, from pre-treatment planning through embryo selection. By combining AI-driven insights with clinical workflows, it is designed to improve consistency, transparency, and patient understanding across the treatment journey.

Embryo Predict™, Alife’s CE-marked AI tool, plays a central role in this approach by supporting embryo assessment for transfer decisions. Using deep learning, it generates an AI score for each embryo, alongside personalized reports for patients.

The platform also includes Success Predictor™, a non-medical device search tool which provides outcome projections before treatment, and Egg Retrieval Report, which offers patients visibility into their evolving chances of success following retrieval. Together, these tools extend patient support across the full IVF journey. The collaboration will also introduce standardized reporting across clinics and for more consistent, data-driven care, alongside the development of educational resources for both patients and physicians.

“Fertility care must continuously evolve to reflect the best available science,” said Francisco Lobbosco, CEO of FutureLife Group. “By integrating AI into our clinical workflow, we are raising the standard of care for the patients and families who trust us.”

“Working with Alife and seeing the results of the platform made the decision clear,” said Amy Barrie, Chief Scientific Officer of FutureLife. “Deploying this platform gives our clinical teams a more objective, data-driven foundation for clinical decisions and strengthens performance across our laboratories.”

“When a leading fertility network makes an institutional commitment to AI-powered fertility treatment, it signals that this technology is moving from experimentation to standard practice,” said Melissa Teran, CEO and Co-Founder of Alife Health. “We are proud to partner with FutureLife as they lead the next phase of data-driven fertility care.”

FutureLife Group performs more than 77,000 IVF cycles annually and operates 60 clinics across 16 countries, employing more than 2,400 specialists. The organization continues to expand its European footprint through organic growth and strategic acquisitions. FutureLife Group is co-owned by CVC and Hartenberg.

Embryo Predict received CE mark certification under the European Union Medical Device Regulation (EU MDR) in October 2025 and is authorized for commercial use across the EU.

About FutureLife GroupFutureLife is one of the leading European providers of IVF, fertility treatments and related genetic services. With 60 well-invested clinics in 16 countries, employing more than 2,100 specialists and performing in excess of 77,000 IVF cycles annually, the group has helped bring more than 185,000 babies into the world since 1991. FutureLife believes in a world where everyone has the freedom to create a family and adopts an evidence-based approach to the innovation of treatment strategies, with a mission focused on ethics and standards. FutureLife is co-owned by CVC and Hartenberg. www.futurelifegroup.com

About Alife HealthAlife Health is modernizing and personalizing the IVF process with cutting-edge AI technology. With partnerships across the top clinics and renowned physicians in the field, Alife is pioneering AI solutions that support embryologists, clinics, and patients on the IVF journey. www.alifehealth.com.

Media ContactFutureLife, pressoffice@futurelifegroup.comAlife Health, press@alifehealth.com

Photo – https://mma.prnewswire.com/media/2972192/Alife_Health_FutureLife.jpg Logo – https://mma.prnewswire.com/media/1718591/Alife_Health_Logo.jpg Logo – https://mma.prnewswire.com/media/2972367/FutureLife_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/futurelife-becomes-first-european-fertility-network-to-adopt-an-end-to-end-ai-fertility-platform-in-partnership-with-alife-health-302762020.html

—

immediapress/pr-newswire